Minotaur Therapeutics

Executive Summary

Minotaur Therapeutics is a preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel targeted immunotherapies for cancer. Founded in 2018, the company leverages advanced biologics engineering to design therapies with improved precision and efficacy. While specific pipeline candidates have not been disclosed, Minotaur's platform aims to address key limitations of current immunotherapies, such as off-target toxicity and resistance. The company operates in the competitive immuno-oncology space, with a mission to deliver more effective treatments for patients. Given its early stage, Minotaur's progress depends on successful preclinical validation and potential partnership or financing opportunities.

Upcoming Catalysts (preview)

• H2 2026Preclinical Proof-of-Concept Data for Lead Candidate40% success
• 2026Series A Financing or Major Partnership50% success
• 2027IND Filing for Lead Program25% success